Search Results
Your search for Joyce F. Liu, MD, MPH,Joyce F. Liu, MD, MPH matches 26 pages
Showing 1 - 26Poor Tolerability Appears to Hinder Benefit of Adavosertib in Uterine Serous Carcinoma
The oral, small-molecule Wee1 kinase inhibitor adavosertib was clinically active but not well tolerated by more than half the patients with recurrent or persistent uterine serous carcinoma in the phase IIb ADAGIO trial. The findings were reported at the Society of Gynecologic Oncology (SGO) 2023...
Expert Point of View: Debra L. Richardson, MD and Joyce F. Liu, MD, MPH
Debra L. Richardson, MD, Associate Professor and Chief of the Section of Gynecologic Oncology, Oklahoma TSET Phase I Program, at the Stephenson Cancer Center, University of Oklahoma, Oklahoma City, discussed the emerging field of antibody-drug conjugates at a session on platinum-resistant ovarian...
Poor Tolerability Appears to Hinder Benefit of Adavosertib in Uterine Serous Carcinoma
The oral, small-molecule Wee1 kinase inhibitor adavosertib was clinically active but not well tolerated by more than half the patients with recurrent or persistent uterine serous carcinoma in the phase IIb ADAGIO trial. The findings were reported at the Society of Gynecologic Oncology (SGO) 2023...
Highlights of the SGO 2023 Annual Meeting on Women’s Cancer
The sun was out, and the weather was beautiful for the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer held in Tampa, Florida, in March 2023. Participants came from across the world for this second hybrid gathering since the COVID-19 pandemic to share ongoing advances in ...
Expert Point of View: Debra L. Richardson, MD and Joyce F. Liu, MD, MPH
Debra L. Richardson, MD, Associate Professor and Chief of the Section of Gynecologic Oncology, Oklahoma TSET Phase I Program, at the Stephenson Cancer Center, University of Oklahoma, Oklahoma City, discussed the emerging field of antibody-drug conjugates at a session on platinum-resistant ovarian...
HRR Mutational Status May Be Prognostic of Survival Outcomes for Women With Recurrent Platinum-Sensitive Ovarian Cancer
Results of a biomarker analysis of the NRG Oncology NRG-GY004 trial were presented during the Society for Gynecologic Oncology’s (SGO) Annual Meeting on Women’s Cancer. The analysis, which occurred as part of a preplanned translational endpoint for the study, concluded that homologous recombination ...
Mismatch Repair–Deficient/Microsatellite Instability–High Recurrent Endometrial Cancer
In this video, Ursula Matulonis, MD; Joyce F. Liu, MD, MPH; and Bobbie J. Rimel, MD, focus on a case of mismatch repair–deficient/microsatellite instability–high recurrent endometrial cancer. They discuss the range of treatment options for patients with mismatch repair–deficient cancer, including...
Mismatch Repair–Proficient Recurrent Endometrial Cancer
Ursula Matulonis, MD; Joyce F. Liu, MD, MPH; and Bobbie J. Rimel, MD, discuss the appropriate management of an older patient with mismatch repair–proficient recurrent endometrioid endometrial cancer, highlighting the importance of histology when determining the best treatment option for patients...
Platinum-Sensitive Recurrent Ovarian Cancer
Ursula Matulonis, MD; Joyce F. Liu, MD, MPH; and Bobbie J. Rimel, MD, discuss a case of a woman with platinum-sensitive recurrent ovarian cancer who was found to have a germline BRCA1 mutation. They address the question of how to choose the optimal chemotherapy regimen for patients who are...
Newly Diagnosed Advanced BRCA-Mutated Ovarian Cancer
In this video, Ursula Matulonis, MD; Joyce F. Liu, MD, MPH; and Bobbie J. Rimel, MD, discuss the use of poly (ADP-ribose) polymerase (PARP) inhibitors in the management of a patient with newly diagnosed, advanced ovarian cancer with a germline BRCA1 mutation. They review recent findings from the...
WEE1 Inhibition in Patients With Recurrent Uterine Serous Carcinoma
In a single-institution phase II trial reported in the Journal of Clinical Oncology, Joyce F. Liu, MD, MPH, and colleagues found that the WEE1 inhibitor adavosertib produced durable responses in women with recurrent uterine serous carcinoma. The investigators stated, “Uterine serous carcinoma is a...
Early Cancer Experience Plants the Seed for a Career in Oncology to Grow for Joyce F. Liu, MD, MPH
As a young girl growing up in central New Jersey, Joyce F. Liu, MD, MPH, a medical oncologist specializing in gynecologic cancers at Dana-Farber Cancer Institute, Boston, dreamed of becoming an astronaut. However, she realized her fear of heights and propensity for motion sickness didn’t jive with...
SGO 2020: WEE1 Inhibitor Shows Activity in Recurrent Uterine Serous Carcinoma
Monotherapy with the experimental WEE1 inhibitor adavosertib has shown activity in patients with advanced recurrent or metastatic uterine serous carcinoma,1 according to data presented during the 2020 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer Webinar Series. The initial ...
ASCO20: Cediranib Plus Olaparib vs Standard-of-Care Chemotherapy for Platinum-Sensitive Ovarian Cancer
Results of the NRG Oncology phase III clinical trial NRG-GY004 indicated that the addition of the investigational agent cediranib to olaparib and standard platinum-based chemotherapy did not improve progression-free survival outcomes for women with platinum-sensitive ovarian cancer; however,...
Nivolumab Plus Bevacizumab in Relapsed Ovarian Cancer
In a phase II trial reported in JAMA Oncology, Joyce F. Liu, MD, MPH, and colleagues found evidence of the activity of combined nivolumab and bevacizumab in relapsed ovarian cancer, with activity appearing to be greater in platinum-sensitive disease. Study Details In the trial, 38 women with...
Nivolumab Plus Bevacizumab in Relapsed Ovarian Cancer
In a phase II trial reported in JAMA Oncology, Liu et al found evidence of the activity of combined nivolumab and bevacizumab in relapsed ovarian cancer, with activity appearing to be greater in platinum-sensitive disease. Study Details In the trial, 38 women with relapsed epithelial ovarian cancer ...
No Advantage to Adding Seribantumab to Paclitaxel in Platinum-Resistant/Refractory Ovarian Cancer, but Subgroup May Benefit
In a phase II study reported in the Journal of Clinical Oncology, Liu et al found no progression-free survival benefit of adding the anti-HER3 (ErbB3) antibody seribantumab to paclitaxel in unselected patients with advanced platinum-resistant or -refractory ovarian cancer. However, exploratory...
SIDEBAR: First Report of Antibody-Drug Conjugate in Advanced Ovarian Cancer
In a related presentation at the AACR Annual Meeting,1 the antibody-drug conjugate DMUC5754A showed encouraging activity in women with ovarian cancer, particularly those with platinum-resistant disease, which currently lacks effective treatment options. The first-in-human phase I study included 44...
Learning to Negotiate the Genomic Complexities of Cancer
The Cancer Genome Atlas (TCGA) Research Network recently reported the results of an integrated analysis of the genomic features of 373 endometrial carcinomas.1 This report joins previously published results of similar analyses in ovarian, breast, and colorectal cancers, squamous cell carcinoma of...
Dana-Farber Receives $900,000 Grant to Research Ovarian Cancer
The Ovarian Cancer Research Foundation has awarded researchers at Dana-Farber Cancer Institute a $900,000 grant to test new combinations of targeted drugs against the disease. Ursula Matulonis, MD, Director of the Gynecological Cancer Treatment Center in the Susan F. Smith Center for Women’s...
Expert Point of View: Joyce F. Liu, MD, MPH, of Dana-Farber Cancer Institute, and Stephen A. Cannistra, MD
In an editorial accompanying publication of the AURELIA study results, Joyce F. Liu, MD, MPH, of Dana-Farber Cancer Institute, and Stephen A. Cannistra, MD, of Beth Israel Deaconess Medical Center, Boston, considered the implications of the benefits observed in the trial and limitations in...
Oral Two-Drug Regimen Appears Promising in Phase II Trial of Recurrent Platinum-Sensitive Ovarian Cancer
An all-oral combination of the investigational agents olaparib and cediranib nearly doubled progression-free survival in platinum-sensitive recurrent ovarian cancer in a National Cancer Institute (NCI)-sponsored randomized phase II trial reported at the 2014 ASCO Annual Meeting.1 The toxicity...
Conquer Cancer Foundation Past Grant Recipients Present Research Advances in Melanoma and Ovarian Cancer at 2014 ASCO Annual Meeting
The Conquer Cancer Foundation has an excellent track record of finding and funding the most promising young investigators. Past recipients Joyce F. Liu, MD, MPH, and Antoni Ribas, MD, PhD, received funding from the Conquer Cancer Foundation early in their career and at the 2014 ASCO Annual Meeting...
Findings of AURELIA Trial Support Consideration of Bevacizumab/Chemotherapy in Carefully Selected Patients With Platinum-Resistant Ovarian Cancer
The recently reported open-label phase III AURELIA trial showed that the addition of bevacizumab (Avastin) to chemotherapy resulted in significant improvements in progression-free survival, the primary study endpoint, and objective response rate in women with recurrent platinum-resistant ovarian...
Novel Drug Combination Shows Activity in Recurrent Ovarian Cancer
A novel pairing of two investigational cancer drugs in patients with recurrent ovarian cancer showed promising activity and had manageable toxicities, according to a phase I trial published online in the European Journal of Cancer. The combination of the poly(ADP-ribose) polymerase (PARP)...
New Type of Experimental Drug Active in Platinum-resistant Ovarian Cancers
The antibody-drug conjugate DMUC5754A, a novel member of a relatively new class of drugs, showed activity in women with ovarian cancer, even those with hard-to-treat, platinum-resistant disease, in a phase I trial presented at the AACR Annual Meeting 2013, held in Washington, DC, April 6 to 10....
